Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4633 Target Snapshot

Potassium voltage-gated channel subfamily A member 3 · SINGLE PROTEIN · Homo sapiens

748Compounds
77Assays
4Approved Drugs
1,133.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P22001. Use UniProt P22001 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P22001 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Potassium voltage-gated channel subfamily A member 3 as ChEMBL target CHEMBL4633, mapped to UniProt P22001. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Potassium voltage-gated channel subfamily A member 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4633
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22001
Potassium voltage-gated channel subfamily A member 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Potassium voltage-gated channel subfamily A member 3 is the right protein anchor across sources, using UniProt P22001 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPotassium voltage-gated channel subfamily A member 3
UniProt AccessionP22001
Component TypeProtein
Sequence Length575 aa

Potassium voltage-gated channel subfamily A member 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Potassium voltage-gated channel subfamily A member 3, mapped to UniProt P22001. Sequence length is 575 aa.

Mapped IDP22001
Review namePotassium voltage-gated channel subfamily A member 3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
Assay Mix

Activity Type Distribution

IC501,048.0
EC5053.0
KD32.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3609094 10.92 IC50 0.012 Preclinical
CHEMBL3609093 10.8 IC50 0.016 Preclinical
CHEMBL3609263 10.74 IC50 0.018 Preclinical
CHEMBL3609033 10.7 IC50 0.02 Preclinical
CHEMBL3608994 10.64 IC50 0.023 Preclinical
CHEMBL3609063 10.64 IC50 0.023 Preclinical
CHEMBL3609272 10.64 IC50 0.023 Preclinical
CHEMBL3609265 10.54 IC50 0.029 Preclinical
CHEMBL3609095 10.51 IC50 0.031 Preclinical
CHEMBL3609266 10.51 IC50 0.031 Preclinical
Distribution

pChEMBL Value Distribution

60
5.0
109
5.5
169
6.0
109
6.5
61
7.0
60
7.5
36
8.0
33
8.5
55
9.0
161
9.5
pChEMBL
Assay Landscape

Assay Landscape

77
Total Assays
669
Tested Compounds
3
Assay Types
Binding — 67 assays, 669 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 54 361 7.2
single protein format 7 252 8.6
assay format 4 45 5.9
cell membrane format 2 11 7.1
Functional — 9 assays, 122 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 6 101 6.7
assay format 3 21 6.4
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine